Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study

Francesco Raspagliesi(Fondazione IRCCS Istituto Nazionale dei Tumori), Domenica Lorusso(Agostino Gemelli University Polyclinic), Anna Myriam Perrone(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Giovanni Scambia(Agostino Gemelli University Polyclinic), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Stefano Bogliolo(University of Pavia), Alice Bergamini(IRCCS Ospedale San Raffaele), Stefano Lepori(Fondazione IRCCS Istituto Nazionale dei Tumori), Pierandrea De Iaco(Clinical Orthopaedics and Related Research), Giuseppe Bifulco(Federico II University Hospital), Gennaro Cormio(Istituto Tumori Bari), Giovanni Fucà(AstraZeneca (Spain)), Giuseppa Maltese(Fondazione IRCCS Istituto Nazionale dei Tumori), Giorgio Bogani(Fondazione IRCCS Istituto Nazionale dei Tumori)
Gynecologic Oncology
November 4, 2016
10.1016/j.ygyno.2016.11.002
Cited by 88

Related Papers

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k